06.23.22 -- Scale Up Cell Therapy Production At The Pace Of Your Business

Despite the emergence of cell and gene therapies (CGTs) as one of the most exciting areas of biotechnology, companies continue to face challenges with technology and costs that threaten right-first-time delivery. ElevateBio, in collaboration with Cytiva, is forging a path forward with a solution to de-risk the development of these novel therapies.

The success of your cell therapies, plasmids, viral vectors, mAbs, or any advanced medicines depends on the scale, flexibility, and establishment of your chosen manufacturing platform. But how do you achieve that? In this panel discussion, you’ll learn from experienced colleagues who share their approaches to capacity expansion and offer tips for your success.

The decision to tackle GMP manufacturing in-house or work with a contract development and manufacturing organization (CDMO) represents a pivotal crossroad in your product’s journey to market. Explore key factors to help you determine which strategy best suits your process, product, and team, as well as some general considerations and tips for succeeding in GMP manufacturing.

The concept of optionality is key to staying flexible in biomanufacturing by keeping your options open and having multiple pathways to take while navigating through this highly uncertain environment. Read how to best assess investments in the biopharma space and how to apply optional approaches.

Most cell therapies still use risky and expensive open, manual processes. This article discusses options for cell therapy process development and validation that minimize risks through quality control (QC), optimization, scaling, closing, automation, and assay development.